Sanofi-Aventis Deutschland GmbH: Upward trend in flu vaccination readiness: Protection for people aged 60 and over remains important – ots Press portal – Advertorials

Frankfurt/Main (ots) – – Representative survey about attitudes towards the flu vaccination by Ipsos on behalf of Sanofi Pasteur – Every second person intends to get vaccinated against flu – The willingness to vaccinate people aged 60 and over is increasing

The willingness to vaccinate at the beginning of the flu season 2021/22 is still high. (1) This is shown by the results of the annual population survey by Sanofi Pasteur: As in the previous year, 51% of those surveyed plan to get vaccinated against flu. In the age group 60 and over, more people are planning to have the vaccine to protect themselves from influenza, which may be serious for them. In mid-September 2021, the Ipsos market research institute surveyed 1,000 men and women aged 16 and over online in the i: omnibus, for the third year in a row.

Flu vaccination is particularly important for people aged 60 and over

The positive attitude towards the flu vaccination runs through all social strata and age groups. Particularly gratifying: The willingness to vaccinate people aged 60 and over has increased by more than 10 percentage points compared to 2019 and, as in the previous year, is over 65% (2020: 66%, 2021: 67%). Many people in this age group actually intend to vaccinate: 58% had themselves vaccinated during the previous 2020/2021 flu season, almost 10 percentage points more than in the 2018/2019 season (50%). (1)

Regular flu vaccinations are particularly important for people over the age of 60 and those who have previous illnesses such as asthma, diabetes or cardiovascular diseases, as they are at increased risk of severe flu courses and long-term complications. (2)

The Standing Vaccination Commission (STIKO) advises everyone over the age of 60 and people with previous illnesses to get vaccinated against flu. In its recommendation for the current flu season, the STIKO has included a high-dose flu vaccination for people aged 60 and over, as they need better protection against the flu due to their weaker immune system. (3)

From the respondents’ point of view, this speaks in favor of the flu vaccination

43% of those who want to get the flu vaccine do so to rule out double infection with COVID-19. About one in three of them would like to avoid flu-related complications and risks; A similarly large group of flu protection advocates cited the protection of family and environment as the reason (36% and 34% respectively) The reason for their decision was given by the general practitioner as the reason for their decision to be vaccinated against influenza, either definitely or probably. (1) At 74%, the vast majority of the German population is generally positive about vaccinations. (1)

In good time and with double protection for the flu season 2021/22

Adequate vaccination rates can lead to community protection for the entire population. For this reason, in addition to people aged 60 and over and people with pre-existing illnesses, everyone should get the flu vaccine who can infect people at increased risk, such as nurses and adult children who are caring for their parents. (4) The best time to have a vaccination appointment is Every vaccination is important and useful from October to December, but also during the flu season until February.

Anyone who has been vaccinated against COVID-19 does not reduce the risk of contracting the flu. According to the current recommendation of the STIKO, the vaccination against COVID-19 can be carried out at the same time as the flu vaccination.

Don’t underestimate flu risks

Nobody should underestimate the flu: Anyone can get infected, as the disease spreads easily through coughing, sneezing or speaking. Three to five million cases of severe flu are reported worldwide each year, and up to 650,000 people die each year from the disease and its consequences. (5) Serious complications of the flu can include pneumonia, blood poisoning, heart attacks and strokes. (6)

credentials

1st population survey of influenza vaccination protection 2021 with n = 1,000 men and women aged 16 and over in Germany, representative of the German online population carried out by IPSOS on behalf of Sanofi Pasteur in September 2021; Representativeness criteria were: gender, age, region.

2. Robert Koch Institute. Report on the epidemiology of influenza in Germany 2018/19 season. https://influenza.rki.de/Saisonberichte/2018.pdf. As of Sep 2019. Retrieved on October 6, 2021.

3. Robert Koch Institute (RKI). Epid Bull. 2021; 1: 3-25.

4. Robert Koch Institute. Epid Bull. 2021; (34): 2-63.

5. World Health Organization. Influenza – estimating burden of disease. https://ots.de/8GiUkG. Stand 2021. Abgerufen am 06.10.2021.

6. Federal Center for Health Education. Influenza vaccination for people aged 60 and over. Retrieved on October 6, 2021.

7th population survey of flu vaccination protection 2019 with n = 1,000 men and women aged 16 and over in Germany, representative of the German online population carried out by IPSOS on behalf of Sanofi Pasteur in September 2019; Representativeness criteria were: gender, age, region.

8th population survey of flu vaccination protection 2020 with n = 1,000 men and women aged 16 and over in Germany, representative of the German online population carried out by IPSOS on behalf of Sanofi Pasteur in September 2020; Representativeness criteria were: gender, age, region.

About Sanofi

Sanofi is a global biopharmaceutical company that helps people with their health challenges. We prevent diseases with our vaccines. We relieve their pain and suffering with innovative medicines. We care for people with rare diseases as well as millions of people with chronic diseases.

With more than 100,000 employees in 90 countries worldwide and more than 9,000 employees in Germany, we translate scientific innovation into medical progress.

About Sanofi Pasteur

Sanofi Pasteur is the world’s largest manufacturer of influenza vaccines. In 2017, Sanofi Pasteur confirmed its leadership position by completing production of more than 200 million doses of seasonal influenza vaccine, or approximately 40 percent of the influenza vaccines sold worldwide. Sanofi Pasteur produces seasonal flu vaccines at four locations: Swiftwater (Pennsylvania, USA), Val de Reuil (France), Ocoyoacac (Mexico City, Mexico) and Shenzhen (China).

Every year, Sanofi Pasteur provides more than a billion vaccine doses, enabling the immunization of more than 500 million people worldwide. As one of the world’s leading companies in the field of vaccines, Sanofi Pasteur, based on its special expertise, produces a portfolio of high quality vaccines that meet the needs of public health. The company can look back on more than a hundred years of history.

MAT-DE-2105095-1.0-10 / 2021

Press contact:

Director BU Communications Stephanie De Felice-Reidegeld Tel.: +49 (69) 305 – 48149 [email protected]

Original content by: Sanofi-Aventis Deutschland GmbH, transmitted by news aktuell

Presseportal-Newsroom: Sanofi-Aventis Germany GmbH

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.